-
The Women's Health Initiative reported the effects on overall mortality in their randomized trial of calcium and vitamin D supplementation.
-
In this issue: Aspirin dose and cardioprotection; uncovering modafinil's abuse potential; proton-pump inhibitors and clopidogrel; FDA actions.
-
Fortunately, at a time when there is an emphasis on evidence-based reasons for medical decisions, more reviews are appearing in the literature looking at various common interventions and the evidence available to support these practices.
-
The primary objective of the PLCO study is to evaluate the impact of annual screening with transvaginal ultrasound (TVUS) and CA125 on ovarian cancer mortality. The study is prospectively following a cohort of more than 34,000 largely postmenopausal women with intact ovaries with an algorithm where either an abnormal CA125 (e" 35 units/mL) or an abnormality on TVUS is considered a positive screen.
-
To incorporate evidence-based guidelines into both practice and research, the Research and Development Committee of the International Urogynecological Association embarked on a lengthy process, which included a literature review, creation of recommendations, incorporation of expert consultant opinion, writing a white paper for association members, final revision, and then publication in its journal.
-
-
In light of an increasing internationally mobile community, the primary care physician may see patients who have recently traveled overseas. This article highlights the manifestations of diseases that, although we may not see them often, can fool us with confusing symptoms.
-
-
Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
Since the risk of gastrointestinal bleeding is increased when clopidogrel is added to aspirin therapy in patients with acute coronary syndromes (ACS), many prescribe proton-pump inhibitors (PPIs) to reduce this risk. However, mechanistic studies suggest that PPIs may reduce the effectiveness of clopidogrel.
